Measuring What Matters in Trial Operations: Development and Validation of the Clinical Trial Site Performance Measure

<b>Background/Objectives:</b> The execution of clinical trials is increasingly constrained by operational complexity, regulatory requirements, and variability in site performance. These challenges have direct implications for the reliability of trial outcomes. However, standardized methods to evaluate site-level performance remain underdeveloped. This study introduces the Clinical Trial Site Performance Measure (CT-SPM), a novel framework designed to systematically capture site-level operational quality and to provide a scalable short form for routine monitoring. <b>Methods:</b> We conducted a multicenter study across six Italian academic hospitals (January-June 2025). Candidate performance indicators were identified through a systematic review and expert consultation, followed by validation and reduction using advanced statistical approaches, including factor modeling, ROC curve analysis, and nonparametric scaling methods. The CT-SPM was assessed for structural validity, discriminative capacity, and feasibility for use in real-world settings. <b>Results:</b> From 126 potential indicators, 18 were retained and organized into four domains: Participant Retention and Consent, Data Completeness and Timeliness, Adverse Event Reporting, and Protocol Compliance. A bifactor model revealed two higher-order dimensions (participant-facing and data-facing performance), highlighting the multidimensional nature of site operations. A short form comprising four items demonstrated good scalability and sufficient accuracy to identify underperforming sites. <b>Conclusions:</b> The CT-SPM represents an innovative, evidence-based instrument for monitoring trial execution at the site level. By linking methodological rigor with real-world applicability, it offers a practical solution for benchmarking, resource allocation, and regulatory compliance. This approach contributes to advancing clinical research by providing a standardized, data-driven method to evaluate and improve performance across networks.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2025-09-26
DOI
https://doi.org/10.3390/jcm14196839
Citations
3
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
9.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Measuring What Matters in Trial Operations: Development and Validation of the Clinical Trial Site Performance Measure

Daniele Napolitano, Alessio Lo Cascio, Francesca Resente, Monica Guberti et al.
3 citations
Journal of Clinical Medicine
Health Systems, Economic Evaluations, Quality of Life
9.39
article

Measuring What Matters in Trial Operations: Development and Validation of the Clinical Trial Site Performance Measure

Daniele Napolitano, Alessio Lo Cascio, Francesca Resente, Monica Guberti, Giorgia Petrucci, Mattia Bozzetti, Nicoletta Orgiana, Rosario Caruso, Silvia Fiorini, Irène Baroni, Vincenzina Mora
article en
3 citations

Abstract

<b>Background/Objectives:</b> The execution of clinical trials is increasingly constrained by operational complexity, regulatory requirements, and variability in site performance. These challenges have direct implications for the reliability of trial outcomes. However, standardized methods to evaluate site-level performance remain underdeveloped. This study introduces the Clinical Trial Site Performance Measure (CT-SPM), a novel framework designed to systematically capture site-level operational quality and to provide a scalable short form for routine monitoring. <b>Methods:</b> We conducted a multicenter study across six Italian academic hospitals (January-June 2025). Candidate performance indicators were identified through a systematic review and expert consultation, followed by validation and reduction using advanced statistical approaches, including factor modeling, ROC curve analysis, and nonparametric scaling methods. The CT-SPM was assessed for structural validity, discriminative capacity, and feasibility for use in real-world settings. <b>Results:</b> From 126 potential indicators, 18 were retained and organized into four domains: Participant Retention and Consent, Data Completeness and Timeliness, Adverse Event Reporting, and Protocol Compliance. A bifactor model revealed two higher-order dimensions (participant-facing and data-facing performance), highlighting the multidimensional nature of site operations. A short form comprising four items demonstrated good scalability and sufficient accuracy to identify underperforming sites. <b>Conclusions:</b> The CT-SPM represents an innovative, evidence-based instrument for monitoring trial execution at the site level. By linking methodological rigor with real-world applicability, it offers a practical solution for benchmarking, resource allocation, and regulatory compliance. This approach contributes to advancing clinical research by providing a standardized, data-driven method to evaluate and improve performance across networks.

Journal of Clinical MedicineVol. 14(19)
University of Rome Tor Vergata (IT), University of Milan (IT), Agostino Gemelli University Polyclinic (IT), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), IRCCS Policlinico San Donato (IT), Istituto Ortopedico Rizzoli (IT), Presidio Ospedaliero (IT), IRCCS Istituto Auxologico Italiano (IT), Ospedale Regina Margherita (IT), Campus Bio Medico University Hospital (IT), La Maddalena (IT)
Openalex Percentile: Top 2%
Health Systems, Economic Evaluations, Quality of Life
9.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.